News Analysis: Interviews, Op-eds, & Editorials
Young, Obese and in Surgery
January 7, 2012, published in the NY Times. This story follows a teenage girl through her lap band surgery, including her less than ideal results. Psychologist and NRC president Dr. Diana Zuckerman is quoted on why these surgeries are very risky for teens. Read More
Consumer group questions review of breast implants
Consumer safety advocates are questioning the Food and Drug Administration about incomplete and seemingly erroneous data used to support the safety of silicone breast implants in an agency review last year. The FDA concluded last summer that silicone-gel implants are basically safe as long as women understand they come with complications. Read More
Women’s health advocates question FDA about missing safety data on silicone breast implants
AP News story on NRC’s letter to Dr. Margaret Hamburg, FDA Commissioner, on the missing data for breast implants. Read More
Insight: Breast implant scandal shows regulators in dark on risk
Reuters, December 29, 2011. With the scandal surrounding France’s Poly Implant Prothese (PIP), questions arise whether there should be a national or worldwide breast implant registry. Read More
FDA Panel Gives Tepid Okay to Birth Control Pill
Medpage Today, December 9, 2011 Read More
Labels For Some Birth Control May Require Stronger Wording
WBALTV, December 9, 2011 Read More
With Doubts, FDA Panel Votes For Yaz and Related Contraceptives
NPR, December 9, 2011 Read More
FDA revokes Avastin approval for breast cancer. Decision leaves some devastated. Drug will remain available to treat other cancers.
Washington Post. November 19, 2011. “The science is clear: Breast cancer patients are more likely to be harmed than helped by Avastin,” said Diana Zuckerman, president of the National Research Center for Women & Families. “The risks of the drug are very substantial and can be fatal, killing patients long before they would otherwise die from the disease. FDA made a scientific decision, and it was absolutely the right decision.” Read More
FDA revokes approval of Avastin for breast cancer
NRC President, Dr. Diana Zuckerman, tells AP about the problems with Avastin. Read More
Lawmakers may relax FDA drug conflict rules
Reuters. November 1, 2011. Dr. Diana Zuckerman, president of the National Research Center for Women & Families, talks about the need for stronger conflict of interest rules for the FDA. Read More